Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Vitamin E, particularly in the form of alpha-tocopheryl acetate, has been investigated as a treatment or supportive therapy for Alzheimer's Disease based on its antioxidant properties. The rationale is that oxidative stress contributes to neuronal damage in Alzheimer's, and Vitamin E, as a lipid-soluble antioxidant, could help protect brain cells from oxidative injury.

Several clinical trials have assessed Vitamin E's efficacy in Alzheimer's Disease. The most notable is the 1997 "Sano et al." study published in the New England Journal of Medicine, which found that high-dose Vitamin E (2000 IU/day) modestly delayed the progression of moderate Alzheimer's Disease compared to placebo. However, subsequent studies, including the "TEAM-AD VA Cooperative Randomized Trial" (Dysken et al., 2014), showed only a small delay in functional decline and no significant effect on cognition or mortality. Some meta-analyses have raised concerns about potential harms, including an increased risk of mortality with high-dose Vitamin E supplementation.

Current clinical guidelines do not recommend Vitamin E as a standard treatment for Alzheimer's due to limited efficacy and safety concerns. While there is a scientific basis and some clinical evidence for its use, the overall support is weak and inconsistent. Thus, Vitamin E’s use in Alzheimer's has scientific rationale and limited evidence but is not strongly validated as effective.

More about Vitamin E (alpha tocopheryl acetate)
More about Alzheimer's Disease

Other ingredients used for Alzheimer's Disease

Other health conditions supported by Vitamin E (alpha tocopheryl acetate)

Products containing Vitamin E (alpha tocopheryl acetate)